Harvest One Share Price, page-478

Satipharm has exclusive rights to use gelpell for cannabis derived products. Phytotech Theraputics has an agreement with Satipharm to distribute "health supplements", and the PTL001 and PTL002 formulations currently undergoing medical trials.


"Gelpell granted Satipharm an exclusive license to develop and sell products using
Gelpell’s proprietary technology for the treatment or prevention of any medical condition or disease in humans and animals and for food and dietary supplements (“Gelpell
IP”). Under the terms of the licence, the parties agreed that all intellectual property generated under the licence will be jointly owned between Gelpell and Satipharm, but Satipharm will maintain exclusivity to any licenced intellectual property.
Satip harm has, in turn, granted Phytotech limited the exclusive rights to exploit the Gelpell IP in the worldwide pharmaceutical field (excluding Canada)."

http://clients3.weblink.com.au/pdf/MMJ/01886877.pdf

Satipharm is 100% owned by Harvest One, and Phytotech limited is 100% owned by MMJ. As I see it, MMJ will reap the longer term profits from IP licencing in the medical field, in the medium term HVST will expand and profit from recreational sales.